<http://webisa.webdatacommons.org/323531873>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<clinicaltrials.gov> .
<http://webisa.webdatacommons.org/prov/43850633>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/323531873> .
<http://webisa.webdatacommons.org/323531873>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/323531873>	<http://www.w3.org/ns/prov#value>	"History of hypersensitivity to any ingredients, including excipients (sucrose, histidine, or polysorbate 20) of the study medication or drugs related to omalizumab (e.g., monoclonal anti-bodies or polyclonal gammaglobulin)" .